Using the highly sensitive approach of dSTORM, we visualized a more than 1.5-fold increase of CD38 surface molecules on MM cells that had escaped treatment with daratumumab (Fig. 5b, c). This evidence concerns the gene CD38 and Miyoshi myopathy.